Finance
Novo nordisk receives FDA warning regarding US inspection in 2025
Published by Global Banking & Finance Review®
Posted on March 10, 2026
2 min readLast updated: March 10, 2026
Quick Summary
Novo Nordisk received an FDA warning letter over a U.S. inspection at its Plainsboro, New Jersey site conducted in early 2025. The company has launched corrective and preventive actions, keeping the FDA informed, and does not expect impacts on production or its previous forecasts.
Novo Nordisk receives FDA warning regarding US inspection in 2025
Details of FDA Warning and Company Response
Background of the FDA Inspection
COPENHAGEN, March 10 (Reuters) - Novo Nordisk said on Tuesday it had received a warning letter from the U.S. Food and Drug Administration regarding an inspection at the Danish drugmaker's site in Plainsboro, New Jersey in early 2025.
Corrective Actions and Communication
The company said it has undertaken a corrective and preventative action plan and has kept the agency informed on its progress.
Details of the Warning Letter
The letter, which the company received on March 6, related to a post-marketing adverse drug experience inspection conducted at the site.
"The Warning Letter largely seeks additional details on these measures to confirm current and future regulatory compliance; it does not make any conclusions about the quality or safety of our medicines," the company said.
Company's Response Timeline
Initial Response to FDA
Novo first responded to the Form FDA 483, a type of inspectional observation document, within the agency's deadline, on March 3, 2025, and has shared seven updates since then.
Additional Inspections and Letters
Bloomington, Indiana Site
The drugmaker also said it received a second letter related to a Good Manufacturing Practice inspection at the site in Bloomington, Indiana in late 2025.
Regulatory Agency Feedback
The Department of Health and Human Services, which oversees the FDA, did not immediately respond to a Reuters request for additional details about the inspections and the contents of the letters.
Outlook and Impact
Novo said it was confident that it will resolve the matters outlined in the warning letter to the agency's satisfaction.
The company does not expect the development to have any impact on its production or forecast shared earlier this year.
(Reporting by Louise Rasmussen in Copenhagen, Mrinalika Roy and Sriparna Roy in Bengaluru editing by Terje Solsvik and Sriraj Kalluvila)
Key Takeaways
- •The FDA inspection at Novo Nordisk’s Plainsboro, NJ facility concluded on February 7, 2025, during which a Form 483 was issued, preceding the warning letter (fda483s.com).
- •Novo Nordisk says it has implemented a corrective and preventative action (CAPA) plan, is in communication with the FDA, and believes the matter will be resolved satisfactorily without affecting production or forecasts as of March 10, 2026 (fda483s.com).
- •This warning follows a broader string of compliance challenges for Novo Nordisk in the U.S., including issues at its Indiana manufacturing site declared 'Official Action Indicated' by FDA and facing its own warning letter, underscoring increased regulatory scrutiny across operations (statnews.com)
References
Frequently Asked Questions about Novo Nordisk receives FDA warning regarding US inspection in 2025
1Why did Novo Nordisk receive a warning letter from the FDA?
Novo Nordisk received a warning letter regarding an inspection at its Plainsboro site by the FDA scheduled for early 2025.
2What actions has Novo Nordisk taken after receiving the FDA warning?
Novo Nordisk has implemented a corrective and preventative action plan and kept the FDA informed on its progress.
3Has Novo Nordisk communicated with the FDA after the inspection?
Yes, Novo Nordisk has kept the FDA informed about its corrective actions and progress.
